Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Monitoring and Testing
- Environmental
- University / Academia / Research
- Manufacturing, Other
- Mining
- Aerospace & Air Transport
- Glassware
- Oil, Gas & Refineries
- Water and Wastewater
- Health and Safety
- Air and Climate
- Government
- Food and Beverage
- Energy
- Construction & Construction Materials
Leukemia Suppliers Near Libya
62 companies found
based inWoodland Hills, CALIFORNIA (USA)
EntroGen offers end-to-end molecular diagnostic solutions by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with proprietary software embedded for key decision ...
Mutations in IDH1/2 can lead to the development and/or progression of various types of cancer including secondary glioblastomas and acute myeloid leukemias (AML). IDH1/2 mutations are linked to abnormal histone and DNA methylation ...
based inParamus, NEW JERSEY (USA)
Starton is an emerging clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Focused on continuous ...
STAR-LLD is being developed to establish the only IMiD (immunomodulatory drug) approved for CLL. CLL is the most common form of leukemia. Lenalidomide has been shown to be efficacious and well tolerated in CLL previous randomized ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to ...
based in, NEW YORK (USA)
'Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug ...
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
In parallel, Stemline is evaluating ELZONRIS in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. However, this ...
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
NOMO-1 established from the bone marrow of a 31-year-old woman with acute myeloid leukemia (AML FAB M5a) at 2nd relapse; described to show strong lysozyme activity in the cytoplasm, phagocytic activities, and cells are responsive to ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells. MVR CAR-T can also be used in patients who relapse ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone ...
based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inSeocho-gu, SOUTH KOREA
Taking the first step in 1945, JW Group has found the market for domestic therapeutic drug based on its philosophy of respecting life and pioneering spirit. We are strengthening our global market competitiveness by developing leading health care ...
Active Ingredients: cyclophosphamide 50mg per 1 ...
based inDaxing District, CHINA
Beijing Challen Biotechnology Co., Ltd. (Challenbio) is a leading Chinese flow cytometer manufacturer, located in Biomedical Base of Daxing District, Beijing. It is a high- technology company specializing in R&D, production and sales of biomedical ...
Our product production process strictly follows relevant standards and undergoes multiple rigorous tests to ensure product quality. We pay great attention to details and use a rigorous attitude to ensure the smooth progress of your experiment or ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal ...
based inLund, SWEDEN
Our mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. We do this by providing powerful visualization-based bioinformatics data analysis tools for ...
Ongoing work to comply with the CE-IVDR (clinical use). The program includes classifier models and supportive gene fusion analysis. Qlucore Diagnostics is a scalable diagnostic solution from data to report, improving clinical? workflow? with ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse large B-cell lymphoma (DLBCL). While most ...
based inVictoria, BRITISH COLUMBIA (CANADA)
Established in 2007, StressMarq Biosciences is a bioreagents company producing high quality, cutting edge research products for the life sciences and drug discovery/biopharma markets. StressMarq is a market leader in the development and ...
Product Name: HER2 Antibody (pTyr877). Description: Rabbit Anti-Human HER2 (pTyr877) Polyclonal. Species Reactivity: Human, Mouse, Rat. Applications: WB, IHC, IP, ELISA. Antibody Dilution: WB (1:250-1:1000); IHC (1:50-1:150); IP (1-2.5 ug per mg ...
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ，providing high-quality and accessible molecular ...
Detection Significance:Detect the resistance mechanism of conventional targeted drugs in patients with chronic myeloid ...